Novartis yanks application from the EMA after regulators say researchers never proved efficacy of their $3.4B dry eye drug

John Carroll

Editor & Founder

Novartis is throwing in the towel on its campaign to get their dry eye disease drug Xiidra (lifitegrast) approved in Europe after regulators concluded that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis yanks application from the EMA after regulators say researchers never proved efficacy of their $3.4B dry eye drug

John Carroll

Editor & Founder

Sign up to read this article for free.

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

FDA approves subcutaneous version of Bristol Myers' Opdivo

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm

No­var­tis yanks ap­pli­ca­tion from the EMA af­ter reg­u­la­tors say re­searchers nev­er proved ef­fi­ca­cy of their $3.4B dry eye drug

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Novartis yanks application from the EMA after regulators say researchers never proved efficacy of their $3.4B dry eye drug

J&J partners on STAT6; AstraZeneca, Daiichi withdraw lung cancer drug EMA app

FDA approves subcutaneous version of Bristol Myers' Opdivo

Sofinnova outlines $550M fund after IPOs and M&A deals

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

BioNTech settles with NIH, UPenn in Covid vaccine disputes and will pay royalties

WuXi AppTec will sell cell and gene therapy business to private equity firm